| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3946927 | Gynecologic Oncology | 2012 | 10 Pages |
ObjectivesTo determine the effect of 5-aza-2′-deoxycytidine (DAC) on human endometrial carcinoma cell (HECC) oncogenicity and demonstrate a molecular mechanism by which DAC modulates HECC oncogenicity.MethodsThe effect of DAC was tested on HECC RL95-2, AN3, Ishikawa and ECC1 cells. The role of 14-3-3σ on HECC oncogenicity in response to DAC treatment was evaluated in RL95-2 and AN3 cells after forced expression or silencing of 14-3-3σ gene expression.ResultsTreatment of HECC with DAC produced non‐cytotoxic cell growth inhibition and G2/M cell cycle arrest. This effect was strongly correlated with increased expression of p21 and 14-3-3σ. Silencing of 14-3-3σ induced cellular proliferation and reduced the effect of DAC on cell cycle arrest in G2/M phases. Conversely, forced expression of 14-3-3σ showed the opposite effect. Furthermore, forced expression of 14-3-3σ in human endometrial cell lines reduced cell growth and colony formation.ConclusionsWe suggest that 14-3-3σ in HECC suppresses cell proliferation and mediates DAC induced G2/M arrest and inhibition of cell proliferation in HECC.
► Anticancer effect of 5-aza-2′-deoxycytidine is associated with upregulation of 14-3-3σ, which modulated by p53 pathway in human endometrial cancer cells. ► 14-3-3σ silencing reduces the potency of DAC in inducing cell cycle arrest in G2/M phase in EC. ► Forced expression of 14-3-3σ in human EC cell line abrogated cell growth, cell cycle transition and colony formation.
